BIODIVERSITY CONSERVATION AND DRUG DISCOVERY IN MADAGASCAR

马达加斯加的生物多样性保护和药物发现

基本信息

批准号：
7907275
负责人：
DAVID GEORGE IAN KINGSTON
金额：
$ 23.24万
依托单位：
VIRGINIA POLYTECHNIC INST AND ST UNIV
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-01 至 2012-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7907275
关键词：
Affect Agrochemicals Area Biocompatible Materials Biodiversity Biological Assay Biological Factors Botanicals Botany Cancer Immunology Science Cardiology Chemistry Communities Country Development Disease Economic Development Endocrinology Exhibits Financial compensation Fractionation Funding Gastroenterology Goals Immunology Institutes Intellectual Property International Journals Knowledge Madagascar Malaria Marines Methods Mission Missouri Modeling Natural Products Chemistry Natural Resources Neurology Pharmacologic Substance Plants Population Property Rights Publishing Pulmonology Research Research Infrastructure Research Institute Research Support Sales Scientist Students Surveys Techniques Training Tuberculosis United States Universities Virginia Work drug discovery forest improved interest international center marine organism microbial nervous system disorder novel oncology programs soil sampling

项目摘要

DESCRIPTION (provided by applicant): The overall goals of this International Cooperative Biodiversity group are to achieve the threefold mission of biodiversity conservation, economic development, and drug discovery in Madagascar. The proposed research integrates the work of seven different associate programs into a coherent whole to achieve these goals. The drug discovery mission will have a threefold approach to collecting biomaterials in Madagascar. Plants will be collected by botanists from Missouri Botanical Garden (MBG) Conservation International (CI) and the Centre National d'Application et des Recherches Pharmaceutiques (CNARP). Marine organisms will be collected by teams from Centre National de Recherches sur l'Environnement (CNRE) and Centre National de Recherches Oceanographiques (CNRO). Microbial strain isolation from soil samples will be carried out by scientists from CNARP after receiving training at DowAgroSciences (DAS). The plants will be extracted by workers at the CNARP, and the marine organisms will be extracted by workers at CNRE and CNRO. Subsequent bioassays, fractionation studies, and chemistry will be carried out by CNARP, Eisai Research Institute (ERI), DAS and Virginia Polytechnic Institute and State University (VPISU) in the interest areas of cancer, immunology, malaria, neurological disease, tuberculosis, and agrochemistry, and royalties will be paid to Madagascar on sales of any pharmaceuticals or agrochemicals that are developed from this work. Pure microbial strains will be cultured by one or both of the industrial partners and active compounds of interest will then be isolated from these culture broths. In addition to the drug discovery work outlined above, the Group will also carry out economic development and biodiversity conservation initiatives in Madagascar. In Madagascar the work will include the completion of biodiversity surveys of well-defined forest preserves, as well as training in botanical methods at MBG, training in microbial techniques at DAS, and training in natural product isolation at VPISU. The work will also involve local stakeholders in decisions about the use of upfront funds contributed by DAS and ERI.

描述（由申请人提供）：这个国际合作生物多样性小组的总体目标是实现马达加斯加的生物多样性保护，经济发展和药物发现的三重任务。拟议的研究将七个不同的联想计划的工作整合到一个连贯的整体中，以实现这些目标。该药物发现任务将在马达加斯加收集生物材料的三倍方法。植物将由密苏里州植物园（MBG）国际保护区（CI）和中心国家D'Application et des Recherches Pharmaceutiques（CNARP）收集植物。海洋生物将由中央国家苏尔环境（CNRE）和中心国家de Recherches海洋学（CNRO）的团队收集海洋生物。在Dowagrosciences（DAS）接受培训后，科学家将从土壤样品中隔离微生物应变。这些植物将由CNARP的工人提取，海洋生物将由CNRE和CNRO的工人提取。随后的生物测定，分级研究和化学将由CNARP，EISAI研究所（ERI），DAS和弗吉尼亚理工学院和州立大学（VPISU）（VPISU）在癌症，免疫学，疟疾，疟疾，神经疾病，神经疾病，结核病等人的销售中的兴趣领域进行。这项工作开发的农业化学物质。纯微生物菌株将由一个或两个工业伙伴进行培养，而感兴趣的活跃化合物将与这些培养汤中分离出来。除了上面概述的药物发现外，该组织还将在马达加斯加执行经济发展和生物多样性保护计划。在马达加斯加，这项工作将包括完成定义明确的森林蜜饯的生物多样性调查，以及MBG的植物学方法的培训，DAS的微生物技术培训以及VPISU的自然产品隔离培训。这项工作还将使当地利益相关者参与有关DAS和ERI贡献的前期资金的决定。